about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Meis­sa ob­tains $30M Se­ries A from Morn­ing­side to test syn­thet­ic bi­ol­o­gy ap­proach to 'elu­sive' RSV vac­cines

6 years ago
Financing
Startups

GSK in­fus­es $120M in­to next-gen man­u­fac­tur­ing fa­cil­i­ties at Up­per Meri­on, PA

6 years ago
Pharma

Cana­di­an star re­searcher Bren­dan Frey bran­dish­es Deep Ge­nomic­s' first AI-dis­cov­ered drug

6 years ago
AI
Discovery

Boehringer In­gel­heim backs Max Planck spin­out in tak­ing a shot at tough class of can­cer tar­gets

6 years ago
Financing
Startups

Com­ing out of Chap­ter 11, Aege­ri­on jumps in­to wel­come arms of Irish phar­ma with big plans, fresh $60M for its drugs

6 years ago
Deals

Cerev­el plots first late-stage move as Pfiz­er drug comes through in PhII Parkin­son's tri­al

6 years ago
R&D

Ex-Retrophin BD chief flips his rare dis­ease start­up on­to Nas­daq via re­verse merg­er with Pro­teon

6 years ago
Deals

Once tout­ed as Lyri­ca ri­val for di­a­bet­ic nerve pain, Ko­re­an biotech's plas­mid prod­uct im­plodes in PhI­II

6 years ago
R&D

Amid Wood­ford de­ba­cle, Im­muno­core cuts val­u­a­tion as it se­cures $74M from Gen­er­al At­lantic — re­port

6 years ago
Financing

Here comes the oral GLP-1 drug for di­a­betes — and No­vo Nordisk wants to price Ry­bel­sus 'at a sim­i­lar lev­el as ...

6 years ago
R&D
Pharma

Astel­las' AML drug wins over CHMP — strength­en­ing lead on Dai­ichi Sankyo

6 years ago
Pharma

Boehringer In­gel­heim en­lists an­oth­er vir­tu­al biotech part­ner for its for­ay in­to reti­nal dis­eases

6 years ago
Deals

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

6 years ago
Financing

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

6 years ago
Financing

Zol­gens­ma did­n't cause an in­fant death, AveX­is ex­ecs say as they spot­light long-term da­ta

6 years ago
R&D
Pharma

Young an­ti-ag­ing field takes big step with Mayo Clin­ic senolyt­ics show­case

6 years ago
R&D

Af­ter tout­ing Gazy­va's po­ten­tial in lu­pus, Roche nabs 'break­through' ahead of PhI­II

6 years ago
Pharma

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

6 years ago
Financing

Bio­gen pulls the plug on prized IPF drug from $562M+ Stromedix buy­out

6 years ago
R&D

Benev­o­len­tAI's lat­est fi­nanc­ing could halve its $2B val­u­a­tion — and that has Wood­ford watch­ers wor­ried

6 years ago
Financing
Startups

Pur­due Phar­ma files for bank­rupt­cy as first step in $10B opi­oid set­tle­ment

6 years ago
Pharma

Rit­ter bombs fi­nal PhI­II for sole lac­tose in­tol­er­ance drug — shares plum­met

6 years ago
R&D

Star founders, in­ves­ti­ga­tors hud­dle around new Boston ac­cel­er­a­tor spot­light­ing young en­tre­pre­neurs

6 years ago
Startups

Chalk up a big win for Bain as Spring­Works IPO tops out at $162M

6 years ago
Financing
First page Previous page 90919293949596 Next page Last page
A service from the Financial Times